Thursday’s trading has closed, but ENZN is being traded in the after-hours session. After-Hours quote »
Data as of 4:00pm ET
| +0.03 / +2.00%|
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. The company engages in the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Its drug-development programs utilize two platforms such as customized PEGylation linker technology and third-generation mRNA-targeting agents utilizing the locked nucleic acid technology. The company receives royalties on marketed products that utilize PEGylation platform, including PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. Enzon Pharmaceuticals was founded by Abraham Abuchowski on September 17, 1981 and is headquartered in Piscataway, NJ.
|George W. Hebard||CEO, Chief Operating & Financial Officer|
|Andrew D. Rackear||Secretary, Chief Compliance Officer & VP|